Dr. Barth has more than 25 years of experience in drug development and most recently served as chief medical officer for Lexeo Therapeutics, a gene therapy company, according to a March 20 news release from Ascidian.
In his new role, Dr. Barth will lead clinical development across the company’s ophthalmology, neurological, neuromuscular and genetically defined diseases pipelines.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.